首页>
外国专利>
METHODS OF DRUG THERAPY SELECTION FOR BREAST CANCER PATIENTS BASED ON HER2 AND HER3 PATHWAY SUBTYPING
METHODS OF DRUG THERAPY SELECTION FOR BREAST CANCER PATIENTS BASED ON HER2 AND HER3 PATHWAY SUBTYPING
展开▼
机译:基于HER2和HER3途径分型的乳腺癌患者药物治疗选择方法
展开▼
页面导航
摘要
著录项
相似文献
摘要
Provided herein is a method for determining whether a human subject with breast cancer will respond to a therapy comprising a tyrosine kinase inhibitor or a biologic. The method includes determining the expression level and/or activation level of various signal transduction molecules such as truncated HER2 protein, full-length HER2 protein, HER3 protein, PI3K protein, and others. The determination of likely response to a tyrosine kinase inhibitor therapy or a biologic therapy involves comparing the expression level and/or activation level of the signal transduction molecule(s) to a reference expression/activation level for the specific signal transduction molecule(s).
展开▼